Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 6/20 | 0.61 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21427272 | 0.90 | CXCR4 (0.55) | CXCR4ADRB1SIGMAR1 | |
| SCHEMBL9213719 | 0.85 | CXCR4 (0.49) | CXCR4ADRB1SIGMAR1 | |
| SCHEMBL20671402 | 0.80 | CXCR4 (0.45) | CXCR4 | |
| SCHEMBL27020388 | 0.80 | KDM4E (0.39) | CXCR4SIGMAR1 | |
| SCHEMBL21427211 | 0.80 | CXCR4 (0.52) | CXCR4ADRB1 | |
| SCHEMBL4364575 | 0.80 | CXCR4 (0.54) | CXCR4ADRB1SIGMAR1 | |
| SCHEMBL1394889 | 0.78 | SLC6A9 (0.42) | EGLN1 | |
| SCHEMBL24618863 | 0.78 | CXCR4 (0.69) | CXCR4ADRB1SIGMAR1 | |
| SCHEMBL9213112 | 0.77 | CXCR4 (0.88) | CXCR4SIGMAR1 | |
| SCHEMBL22887713 | 0.76 | SLC6A9 (0.41) | EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218852-A1 | NOVEL RADIOLABELLED CXCR4-TARGETING COMPOUNDS FOR DIAGNOSIS AND THERAPY | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2022-07-14 | — | — | US | disclosed |
| US-10981912-B2 | Macrocyclic ligands with picolinate group(s), complexes thereof and also medical uses thereof | GUERBET (FR) | 2021-04-20 | — | — | US | disclosed |
| US-20200123155-A1 | MACROCYCLIC LIGANDS WITH PICOLINATE GROUP(S), COMPLEXES THEREOF AND ALSO MEDICAL USES THEREOF | UNIVERSITE DE BRETAGNE OCCIDENTALE (FR) | 2020-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218852-A1 | NOVEL RADIOLABELLED CXCR4-TARGETING COMPOUNDS FOR DIAGNOSIS AND THERAPY | CXCR4, CXCR1, FPR1 | CXCR4 1/4885EGLN1 663/4885ADRB1 749/4885 |
| US-10981912-B2 | Macrocyclic ligands with picolinate group(s), complexes thereof and also medical uses thereof | PYGL, PPIG, PPIB | CXCR4 622/4885EGLN1 2494/4885ADRB1 2624/4885 |
| US-20200123155-A1 | MACROCYCLIC LIGANDS WITH PICOLINATE GROUP(S), COMPLEXES THEREOF AND ALSO MEDICAL USES THEREOF | PYGL, PPIG, PPIB | CXCR4 622/4885EGLN1 2494/4885ADRB1 2624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.